Key result
Serum MCP-1 levels at a cut-off of 194 pg/mL were not associated with 90-day major adverse cardiovascular events in patients with non-low-risk chest pain (OR 0.88; 95% CI 0.43-1.79).
Why the study?
Prior studies suggested MCP-1 may aid risk stratification in ED chest pain patients, prompting investigation of whether it predicts 90-day MACE in non-low-risk patients.
Does serum MCP-1 predict 90-day MACE in non-low-risk ED patients with chest pain?
Population
40 cases and 179 controls evaluated for ACS with HEAR score ≥4 or CAD across eight US EDs
Comparison
Patients with 90-day MACE vs frequency-matched controls without MACE
Design
Nested case-control study within a prospective multicentre cohort
Follow-up
90 days
Authors
Loading...
Does not support MCP-1 testing for risk stratification in non-low-risk chest pain; hypothesis-generating and requires prospective validation.
Case-Control (n=219)
Yes
Does serum MCP-1 predict 90-day MACE in non-low-risk ED patients with chest pain?
Odds Ratio: 0.88 (95% CI 0.43–1.79)
Serum MCP-1 levels are not predictive of 90-day major adverse cardiovascular events in non-low-risk emergency department patients presenting with chest pain.
Ashburn et al. (2021) conducted a case-control in Non-low-risk chest pain / Acute coronary syndrome (n=219). Serum monocyte chemoattractant protein-1 (MCP-1) ≥194 pg/mL vs. MCP-1 <194 pg/mL was evaluated on 90-day major adverse cardiovascular events (all-cause death, myocardial infarction or revascularisation) (OR 0.88, 95% CI 0.43 to 1.79). Serum MCP-1 levels at a cut-off of 194 pg/mL were not associated with 90-day major adverse cardiovascular events in patients with non-low-risk chest pain (OR 0.88; 95% CI 0.43-1.79).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: